Search

Your search keyword '"Arend, Rebecca C."' showing total 355 results

Search Constraints

Start Over You searched for: Author "Arend, Rebecca C." Remove constraint Author: "Arend, Rebecca C."
355 results on '"Arend, Rebecca C."'

Search Results

3. Association of allostatic load with overall survival in epithelial ovarian cancer

7. Proteogenomic insights suggest druggable pathways in endometrial carcinoma

9. Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer.

10. Five-Year Relative Survival Rates of Women Diagnosed with Uterine Cancer by County-Level Socioeconomic Status Overall and across Histology and Race/Ethnicity.

12. Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research

14. Abstract A017: An analysis of 13 independently performed assays to measure homologous recombination deficiency using 90 freshly extracted high grade serous ovarian tumors: findings from the friends of cancer research hrd harmonization project

15. Abstract A021: Pilot study of daily exemestane in patients with Endometrial Intraepithelial Neoplasia (EIN) or grade 1 endometrial cancer

16. Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer

26. Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector

27. Proteogenomic insights suggest druggable pathways in endometrial carcinoma

28. Heparan sulfate modifications of betaglycan promote TIMP3-dependent ectodomain shedding to fine-tune TGF-β signaling.

34. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

35. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

39. Supplementary Table 1 from Effect of Niclosamide on Basal-like Breast Cancers

40. Data from Effect of Niclosamide on Basal-like Breast Cancers

41. Supplementary Figure 1 from Effect of Niclosamide on Basal-like Breast Cancers

42. Supplementary Figure 3 from Effect of Niclosamide on Basal-like Breast Cancers

43. Supplementary Figure 5 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

44. Supplementary Tables 1 - 7 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

45. Data from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

46. Supplementary Table 2 from Effect of Niclosamide on Basal-like Breast Cancers

47. Supplementary Figure 5 from Effect of Niclosamide on Basal-like Breast Cancers

48. Supplementary Figure 2 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

49. Supplementary Figure 4 from Effect of Niclosamide on Basal-like Breast Cancers

50. Supplementary Figure 1 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Catalog

Books, media, physical & digital resources